Science Pool

Continuous Biomanufacturing Reduces Environmental Impact

Download the highlights from our DCAT presentation to learn how continuous biomanufacturing reduces the environmental impact of antibody production.

The continuous manufacturing of therapeutic antibodies in agile facilities with a small cleanroom footprint allows:

  • 67% reduction in facility footprint
  • 50% less process water
  • 65% less plastic waste
  • 73% lower CO2 emissions

Just-Evotec Biologic’s unique continuous biomanufacturing platform for antibody therapeutics and innovative J.POD facility design are reducing manufacturing costs and increasing the sustainability of bioproduction.

View the presentation to learn more!

Sounds interesting?
Enter your details below to continue reading…

By clicking on ‘Continue’ I agree that my data is being transferred to the Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our Privacy Policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below:

Join our community

Discover the exclusive benefits on offer if you join our community.